Concise report

Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset

Sarah L. Tansley, Zoe E. Betteridge, Gavin Shaddick, Harsha Gunawardena, Katie Arnold, Lucy R. Wedderburn and Neil J. McHugh, on behalf of the Juvenile Dermatomyositis Research Group

Abstract

Objective. Calcinosis is a major cause of morbidity in JDM and has previously been linked to anti-NXP2 autoantibodies, younger age at disease onset and more persistent disease activity. This study aimed to investigate the clinical associations of anti-NXP2 autoantibodies in patients with JDM stratified by age at disease onset.

Methods. A total of 285 patients with samples and clinical data were recruited via the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-NXP2 was determined by both immunoprecipitation and ELISA. Logistic regression analysis was performed to assess the age-dependent relationship between anti-NXP2 and the development of calcinosis and disease activity measures.

Results. We identified anti-NXP2 autoantibodies in 56 patients (20%). While in all patients younger age at disease onset was associated with an increased risk of calcinosis and this relationship was nearly linear, anti-NXP2 autoantibodies substantially increased the risk of calcinosis across all ages (P = 0.025) and were detectable prior to calcinosis development. Children with anti-NXP2 autoantibodies had a greater degree of weakness (median lowest ever Childhood Myositis Assessment Score 29.6 vs 42) and were less likely to be in remission at 2 years post-diagnosis. No difference in disease activity was seen 4 years post-diagnosis.

Conclusion. Children diagnosed at a young age have a high risk of calcinosis regardless of autoantibody status. However, the presence of anti-NXP2 autoantibodies substantially increases the risk of calcinosis across all ages and is associated with disease severity.

Key words: juvenile dermatomyositis, autoantibody, calcinosis, age.

Introduction

Our group has previously demonstrated that antibodies to a 140 kDa protein detected by protein immunoprecipitation (known as anti-p140 or P140) in JDM were strongly associated with the development of calcinosis, a major cause of morbidity [1]. The presence of autoantibodies to a 142 kDa antigen (anti-MJ) in JDM has also been shown by others to be associated with a severe disease course, worse functional status and persistent disease activity [2]. It is now clear that the target of these autoantibodies is a 140 kDa protein, NXP2 (molecular weight 140 kDa). Anti-NXP2 autoantibodies are common in JDM and identifiable in 13/23% of patients [1, 2].

JDM is a heterogeneous disease and autoantibodies are potentially useful biomarkers to divide patients into homogeneous subgroups and inform on prognosis. Anti-NXP2 autoantibodies are of particular interest, given their...
frequency in JDM and their association with important disease features such as calcinosis, a major cause of morbidity. In addition to autoantibody status, age at disease onset has also been shown to influence the clinical phenotype and overall prognosis in JDM, although the nature of the relationship between age at disease onset and outcome has been variably reported [3, 4].

Here we analyse the clinical associations of anti-NXP2 measured by ELISA and protein immunoprecipitation within an extended and large cohort of juvenile myositis patients stratified by age of onset. We specifically assess the relationships between autoantibody status, calcinosis and disease activity.

Methods

Patients

Patient serum samples and clinical data were obtained through the UK Juvenile Dermatomyositis Cohort and Biomarker Study (JDCBS). The JDCBS is a large cohort of UK patients with idiopathic inflammatory myopathies (IIMs), the majority with JDM [5]. Patients are recruited consecutively on presentation to paediatric rheumatology departments across the UK. Children and young people ≤16 years of age are included based on a diagnosis of definite or probable JDM or PM by Bohan and Peter criteria [6], as well as JDM or PM with overlap CTD features. Multicentre research ethics approval was obtained for the JDCBS and parental consent for children and consent or age-appropriate assent was obtained for all patients in accordance with the Declaration of Helsinki. The JDCBS Steering Committee approved this project and biological samples and clinical data were provided in accordance with JDCBS ethics and consent.

Remission in JDM was defined as a full-strength Childhood Myositis Assessment Score (CMAS) >48 [7], the absence of skin disease (no rash, no Gottron’s, no oedema and no ulceration) and a Physician’s Global the absence of skin disease (no rash, no Gottron’s, no oedema and no ulceration) and a Physician’s Global

immunoprecipitation

Autoantibody detection

Immunoprecipitation of radio-labelled K562 cells was performed on all samples to determine the presence of autoantibodies. Anti-NXP2 ELISA was subsequently performed on all samples. Patients were classified as anti-NXP2 positive if a 140 kDa band was seen on immunoprecipitation and anti-NXP2 ELISA was subsequently positive.

Immunoprecipitation

Ten microlitres of sera were mixed with 2 mg of protein A–Sepharose beads (Sigma, St Louis, MO, USA) in immunoprecipitation (IPP) buffer (10 mM Tris–HCl, pH 8.0, 500 mM NaCl, 0.1% v/v Igepal) at room temperature for 30 min. Beads were washed in IPP buffer prior to the addition of 120 μl of [35S]methionine-labelled K562 cell extract in IPP buffer. Samples were mixed at 4°C for 2 h. Beads were washed in IPP buffer and Tris-buffered saline (TBS) (10 mM Tris–HCl, pH 7.4, 150 mM NaCl) before being resuspended in 50 μl of SDS sample buffer (Sigma). After heating, proteins were fractionated by 9% SDS-PAGE gels, enhanced, fixed and dried. Labelled proteins were analysed by autoradiography.

ELISA

ELISA was conducted as previously described [9], with some modifications. Ninety-six-well polystyrene plates were coated with rNXP2 (Origene Technologies, Rockville, MD, USA) at 4°C for 16 h. Samples were diluted to 1:200. Secondary antibodies were conjugated goat anti-human IgG/M (Sigma). Tetramethylbenzidine liquid substrate (Sigma) was then added. All samples were tested in duplicate and optical density was read using an automatic plate reader. The negative cut-off was defined as >3 s.d. above the mean of 42 normal healthy (adult) serum controls.

Data analysis

Multivariate regression analyses were performed using generalized additive models within R [10], which allows for the possibility of non-linear relationships between covariates and response variables [11]. Within this framework, models were used to assess the significance of age at disease onset and anti-NXP2 in relation to calcinosis as well as disease outcome 2 and >4 years post-diagnosis. Disease duration was adjusted for. Potential differences between two groups were assessed using chi-squared analysis with Yates’s continuity correction. The Mann–Whitney U test was used to compare non-normally distributed continuous data.

Results

Demographic data and key findings are summarized in Table 1.

Autoantibody detection

Of the 365 patients enrolled in the JDCBS at the time of analysis, 285 (78%) had both data and serum available. This group was representative of the cohort as a whole, showing no significant differences in gender (72% vs 68% female), age at disease onset (median 6.2 vs 6.7 years) or JDM clinical type (12% vs 14% JDM overlap) compared with those patients not analysed.

Anti-NXP2 autoantibodies were identified in 56/285 (20%) patients. Two further patients were positive by anti-NXP2 ELISA but did not have a 140kDa band on immunoprecipitation. Further analysis was carried out on only those patients definitively positive using both techniques.
**Table 1** Demographic data and key findings of 285 patients analysed

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Anti-NXP2 positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n/N (%)</td>
<td>206/285 (72)</td>
<td>41/56 (73)</td>
</tr>
<tr>
<td>IIM subtype*, n/N (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DM</td>
<td>242/285 (85)</td>
<td>55/56 (98)</td>
</tr>
<tr>
<td>PM</td>
<td>1/278 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td>Overlap</td>
<td>33/285 (12)</td>
<td>1/56 (2)</td>
</tr>
<tr>
<td>Age at onset, average (IQR), years</td>
<td>6.2 (4–10)</td>
<td>6.5 (4–10)</td>
</tr>
<tr>
<td>Time to diagnosis, average (IQR), months</td>
<td>4 (2–10)</td>
<td>4 (2–10)</td>
</tr>
<tr>
<td>Length of follow-up, average (IQR), years</td>
<td>9 (5–12)</td>
<td>9 (5–12)</td>
</tr>
<tr>
<td>Proportion with calcinosis, n/N (%)</td>
<td>94/283 (29)</td>
<td>24/56 (43), (P = 0.025)</td>
</tr>
<tr>
<td>Lowest ever CMAS score, average (IQR)</td>
<td>40 (27–48)</td>
<td>29.6 (18–43), (P &lt; 0.001)</td>
</tr>
</tbody>
</table>

IQR: interquartile range; IIM: idiopathic inflammatory myopathy; CMAS: Childhood Myositis Assessment Score. *In addition to the diagnostic categories listed, nine juvenile patients were labelled as other IIM or focal myositis. †This patient had JDM–scleroderma overlap. Bold text indicates significant \(P\)-values. Demographic data were similar between anti-NXP2-positive and -negative groups.

**Calcinosis**

Overall, 33% of patients developed calcinosis during the follow-up period. Age at disease onset influenced the likelihood of calcinosis allowing for the duration of disease and there was a significant decrease in calcinosis with increasing age at disease onset [odds ratio (OR) 0.90, 95% CI 0.83, 0.97, \(P = 0.005\)]. Furthermore, this relationship with age proved to be near linear, a striking result given the flexibility of the model meant there were no prior constraints on its shape (Fig. 1).

There was a significant association with anti-NXP2 autoantibodies and calcinosis: 43% anti-NXP2-positive patients developed calcinosis vs 30% anti-NXP2-negative patients (OR 2.10, 95% CI 1.10, 4.01, \(P = 0.025\) unadjusted for age, \(P = 0.039\) adjusted). The presence of anti-NXP2 autoantibodies increased the risk of calcinosis after allowance for the possible effects of other variables, including age.

As some patients were recruited an appreciable time after their initial diagnosis, information on when calcinosis was first noted was not always available. However, seven children with anti-NXP2 autoantibodies developed calcinosis after their first study visit and all of these had anti-NXP2 autoantibodies present in blood samples predating calcinosis development (taken 2 months–4 years after disease onset). The average time to develop calcinosis in this group was 5.3 years (range 1.2–13 years). Thirty-two children without anti-NXP2 autoantibodies developed calcinosis after their first study visit and the average time to calcinosis was similar at 4.1 years after disease onset (range 0–10.9 years).

**Muscle weakness**

Children with anti-NXP2 autoantibodies had a lower median lowest ever CMAS, corresponding to a greater degree of muscle weakness, compared with those without anti-NXP2 autoantibodies [29.6 (interquartile range (IQR) 18–43) vs 42 (IQR 31–48)] and this was statistically significant \(P < 0.001\). Furthermore, 53% of children with anti-NXP2 had a lowest ever CMAS ≤ 30, corresponding to a moderate or severe degree of weakness [7], compared with just 25% of those children without anti-NXP2 \(P < 0.001\).

**Disease outcome in JDM**

Disease outcome was assessed 2 years post-diagnosis and at the last clinic visit, providing this was at least 4 years post-diagnosis (mean 7.9 years). Data at 2 years post-diagnosis were not yet available in children who had been diagnosed with JDM < 2 years previously, had been recruited into the study > 2 years post-diagnosis or had not been reviewed 20–28 months post-diagnosis. Information was available for 152 children 2 years post-diagnosis (25 with anti-NXP2 autoantibodies) and 136 children > 4 years post-diagnosis (24 with anti-NXP2 autoantibodies).

Using our own predefined definition of remission, children with anti-NXP2 antibodies were less likely to be in remission 2 years post-diagnosis compared with those without anti-NXP2 (8% vs 32%; OR 0.23, 95% CI 0.05, 1.05, \(P = 0.04\)). Using the recently proposed PRINTO definition of disease inactivity in JDM [8], fewer children with anti-NXP2 had inactive disease 2 years post-diagnosis (37.5% vs 48%), but this did not reach significance. Outcomes > 4 years post-diagnosis were similar in the
two groups, irrespective of the definition used (our own criteria, 47% vs 50%; PRINTO criteria, 72% vs 73%).

**Discussion**

This study shows that anti-NXP2 autoantibodies are the most common autoantibody identifiable in our JDM cohort and can be identified in one in five UK children with JDM. They are a potentially important clinical biomarker and can both facilitate diagnosis and provide important prognostic information, particularly with regard to calcinosis development.

Younger children with JDM are believed by some specialist clinicians to have more aggressive disease, but recent studies have challenged this view [4]. We have clearly demonstrated that children presenting at a younger age have a higher risk of developing calcinosis, a major cause of morbidity. The presence of anti-NXP2 autoantibodies substantially increases the risk of calcinosis across all ages.

Anti-NXP2 autoantibodies were associated with a greater degree of muscle weakness as determined by CMAS, suggesting more severe disease. This difference is of clinical significance and children with anti-NXP2 autoantibodies were more likely to have a moderate or severe degree of clinical weakness [7].

In JDM, the development of calcinosis has previously been associated with a delayed diagnosis, a chronic disease course and inadequately treated disease [12]. In our cohort, no difference in time from symptom onset to diagnosis was identified between the anti-NXP2-positive and anti-NXP2-negative groups. We investigated the prevalence of disease remission in JDM at two time points using two different definitions of disease inactivity. While a significant association between anti-NXP2 autoantibody status and more persistent disease activity 2 years post-diagnosis was suggested using our own definition of remission, the CIs were wide. We were unable to clearly demonstrate a significant relationship using the recently proposed PRINTO criteria, although the same trend existed. Persistent disease activity remains a possible mechanism driving calcinosis development in children with anti-NXP2 autoantibodies, but larger patient numbers and validated remission criteria are required to firmly establish the nature of any association.

In summary, anti-NXP2 autoantibodies are associated with features of severe disease in JDM. The development of calcinosis in JDM is influenced by both age at disease onset and anti-NXP2 autoantibody status and both factors must be considered when attempting to predict the risk of this clinically important complication.

**Rheumatology key messages**

- Earlier age at disease onset is associated with greater risk of calcinosis in JDM.
- Anti-NXP2 substantially increases the risk of calcinosis across all age groups in JDM.
- Anti-NXP2 autoantibodies are associated with features of severe disease in JDM.

**Acknowledgements**

The UK Juvenile Dermatomyositis Cohort and Biomarker Study (JDCBS) has been supported by generous grants from the Wellcome Trust UK (085860), Action Medical Research UK (SP4252), the Myositis Support Group UK, Arthritis Research UK (14518) and the Henry Smith Charity. The JDCBS has been adopted onto the Comprehensive Research Network through the Medicines for Children Research Network (www.mcrn.org.uk). S.T. and the serotyping of much of the JDCBS cohort were funded by the British Medical Association (Doris Hillier grant 2012). A list of the members of the Juvenile Dermatomyositis Research Group is available as supplementary material at *Rheumatology* Online.

**Disclosure statement:** The authors have declared no conflicts of interest.

**Supplementary data**

Supplementary data are available at *Rheumatology* Online.

**References**


Clinical vignette

Ultrasonographic diagnosis of posterior interosseous nerve entrapment due to ganglion cyst in a patient with rheumatoid arthritis

A 74-year-old man with RA was seen due to weakness in the fingers of his right hand. He was receiving LEF (20 mg/day) and prednisolone (10 mg/day) treatment. Physical examination showed weakness (1/5) of the finger extensors (drop finger). Laboratory tests yielded increased CRP (6.4 mg/l, normal range 0–3), ESR (56 mm/h, normal range 0–20) and RF (192 IU/ml, normal range 0–14) levels. Electrodiagnostic evaluations were consistent with severe and partial neuropathy of the right posterior interosseous nerve (PIN). US imaging clearly demonstrated a ganglion cyst compressing the PIN (Fig. 1). As the ganglion could not be drained, US-guided intervention was finalized with intralesional betamethasone injection. The patient refused surgery, as his pain (but not weakness) subsided.

A ganglion or synovial cyst is a benign tumour-like mass that usually occurs near the joints or tendon sheaths, most commonly in the wrist and hand [1]. Although they are usually asymptomatic, they can manifest with various complaints, especially if they cause any sort of nerve entrapment [2]. Herein we show that US is a convenient imaging tool for illustrating not only the clinical conditions related to RA (rheumatoid nodules, synovial cysts, etc.) but also secondary/pertinent complications of such manifestations, i.e. peripheral nerve compression.

Funding: None.

Disclosure statement: The authors have declared no conflicts of interest.

Timur Ekiz1, Gökhan Tuna Öztürk1, Süha Yalçın1, Gülay Kinikli2 and Levent Özçakar3
1Department of Physical Medicine and Rehabilitation, Ankara Physical Medicine and Rehabilitation Training and Research Hospital, 2Department of Rheumatology, Ankara University Medical School and 3Department of Physical Medicine and Rehabilitation, Hacettepe University Medical School, Ankara, Turkey.

Correspondence to: Timur Ekiz, Ankara Physical Medicine and Rehabilitation Training and Research Hospital, Department of Physical Medicine and Rehabilitation, Türkocäßi Street No: 3, 06230 Ankara, Turkey. E-mail: timurekiz@gmail.com

References